Tempus publishes investor deck on planned Personalis acquisition to expand MRD testing platform
TEM•Tempus outlines terms of planned Personalis acquisition
Tempus outlined plans to buy Personalis for $16.25 per share, valuing the deal at $1.7 billion, or $1.5 billion net.
Consideration is set as TEM stock with up to 50% cash at Tempus’ option; the floating exchange ratio is capped at 0.3356 TEM shares.
The transaction is expected to close no earlier than Q4 2026, subject to a Personalis shareholder vote and regulatory clearance.
Deal aims to expand MRD testing within Tempus’ oncology platform
The deal targets tighter integration of Personalis’ MRD testing into Tempus’ precision oncology platform, expanding exposure to a $20+ billion U.S. MRD market.
Personalis cited more than 35,000 total tests, 10,384 Q2 volume, 33% sequential growth, and assay sensitivity down to 1.67 parts per million.
